Amgen Inc.

Richard T Lewis

Ning Xi

Jennifer Rebecca Allen

Patricia Lopez

Qingyian Liu

Shon Booker

Robert Michael Rzasa

Qiufen May Xue

Ryan D White

Wenge Zhong

Yuan Cheng

Ana Elena Minatti

Ted Charles Judd

Aaron C Siegmund

Angel Guzman-Perez

Laurie B Schenkel

Paul E Harrington

Tae-Seong Kim

Alessandro Boezio

Randall W Hungate

Shannon Rumfelt

Karina Romero

Deborah Choquette

Jason Brooks Human

Michele Potashman

Philip R Olivieri

Derin C D'amico

Zihao Hua

Oleg Epstein

Xiao Mei Zheng

David Bauer

John Stellwagen

Christiane M Bode

Stephanie Springer

Julia Lohmann

Liu Longbin

Mard H Norman

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, A, A, A, R, R, R, Rand n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II. 

Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use

Growing community of inventors

Houston, TX, United States of America

Richard T Lewis